Marker Therapeutics Inc. (MRKR) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 10% of 52W Range • RSI-14 at 44.7 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While MRKR currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($1.06) forces dealer call-delta covering toward $2.58.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Marker Therapeutics Inc. (MRKR) advanced +1.00% to $1.01, trading at 10% of its 52-week range ($0.84 – $2.46). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platformHOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therap
Marker Therapeutics, Inc. (NASDAQ:MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MRKR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MRKR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Marker Therapeutics Inc. (MRKR) ranks #394 by composite RQD confidence (48/100, grade D) and #846 by equity capitalization ($16.8M). Within this direct 5-issuer industry benchmark cohort, MRKR leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with MRKR at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MRKR
ACTIVE
Marker Therapeutics Inc. | D | 48/100 | — | — | -35.0% | +1.00% | $16.8M | Benchmark Subject |
| NEUP Neuphoria Therapeutics Inc. | E | 32/100 | — | — | -11.8% | -8.93% | $16.6M | /neup-vs-mrkr → |
| AEON AEON Biopharma Inc. (Class A) | D | 48/100 | — | — | -35.0% | +11.36% | $17.4M | /aeon-vs-mrkr → |
| RADX Radiopharm Theranostics Limited | C- | 61/100 | — | — | — | +17.52% | $16.1M | /radx-vs-mrkr → |
| JAGX Jaguar Health Inc. | E | 31/100 | — | 67.2% | -35.0% | -2.86% | $15.9M | /jagx-vs-mrkr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Marker Therapeutics Inc. (MRKR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.2M, operating cash flow of -$12.0M, and free cash flow of -$12.0M (-10.1% YoY). On the balance sheet, MRKR closed FY2025 with $19.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$12.2M | -$12.0M | -$12.0M | $19.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$10.7M | -$10.9M | -$10.9M | $22.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$8.2M | -$16.4M | -$16.4M | — | — |
As of 2026-11-01, Marker Therapeutics Inc. (NASDAQ: MRKR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $1.01 (+1.00% 1D, market cap $16.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MRKR ranks #394 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MRKR carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NEUP (Neuphoria Therapeutics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -11.8%, cap $16.6M) and AEON (AEON Biopharma Inc. (Class A)) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $17.4M). Among the 5-stock peer group, MRKR leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
Per MRKR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001094038), Marker Therapeutics Inc. generated $0 in revenue, -$12.2M in net income, and -$12.0M in free cash flow against $19.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MRKR last traded at $1.01 (+1.00% on volume of 72,941 shares), positioning the stock -12.17% below its 50-day simple moving average ($1.15) and -26.28% below its 200-day simple moving average ($1.37). Across its 52-week range of $0.84 to $2.46, MRKR sits at the 10.5% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.14).
Why MRKR Stock advanced +1.00% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.